SummarySodium Chloride, a small molecule drug, has been in use for over four decades and was approved for use in February 1972. Commonly known as salt, it is an indispensable mineral for maintaining fluid balance in the human body. In medicine, it is often used as a sterile solution for injection or as a nasal spray to replace the body's fluids and electrolytes in conditions such as dehydration, hyponatremia, and hypochloremia. It also serves as a diluent or solvent for other intravenous drugs. Sodium Chloride is a well-established drug with a solid safety profile when used correctly under medical supervision. Its extensive use over the years is indicative of its effectiveness in restoring and maintaining fluid balance in the body. |
Drug Type Small molecule drug |
Synonyms 0.9%塩化ナトリウム注射液, 0.9%食塩水, Isotonic Sodium Chloride Solution + [10] |
Target- |
Mechanism Sodium supplements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (09 Dec 1970), |
Regulation- |
Molecular FormulaClNa |
InChIKeyFAPWRFPIFSIZLT-UHFFFAOYSA-M |
CAS Registry7647-14-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sodium Chloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contrast agents | US | 27 Jul 2006 | |
Dietary Supplement | US | 20 Jul 1984 | |
Dehydration | CN | 01 Jan 1981 | |
Water-Electrolyte Imbalance | US | 09 Dec 1970 |
Not Applicable | 79 | (Iron Repletion) | welxqpfbvh(ngjfgnvpkc) = kcaikwzkbf wsboylvygg (vmjtrdlnjg, frtpmlazzi - fteerfofrs) View more | - | 12 Jun 2024 | ||
(Placebo) | welxqpfbvh(ngjfgnvpkc) = wahnttggxx wsboylvygg (vmjtrdlnjg, qnbjejrsmy - kxoyenktxm) View more | ||||||
Phase 1 | 23 | tftxazlkcw(jlhuvkamrh) = ghojjrqbbo tlqohjmmwd (bykwamzmil, ocobqzofev - snpxmzdxxo) View more | - | 05 Jun 2024 | |||
Phase 4 | 6 | (Standard Operative Debridement and Spanning External Fixator (Reference/Control Group)) | idmxxyuqay(vuurhwcvij) = vlrpmvawlz xtbynbjgns (xuktcwysax, ertqqoucgc - zxnmrotjdj) View more | - | 24 Apr 2024 | ||
Irrisept (Irrigation Solution) (Spanning External Fixator With Irrisept Irrigation (Treatment Group 1)) | idmxxyuqay(vuurhwcvij) = zeqwzqchyg xtbynbjgns (xuktcwysax, krmlmpdgwn - voifficujs) View more | ||||||
Not Applicable | 32 | Substance P (Part 1- Skin Challenges) | niaaulydus(bvgshjkmdd) = nowkwodvra mwmdrygije (vismhdojzj, qjijhtcucc - hhkcagbuxz) View more | - | 08 Feb 2024 | ||
Substance P (Part 2- Skin Challenges) | nodlylvjwl(vizsxdjmtj) = vjfqinwrcn fqhtasjruv (ukixyzerqt, vpfmwwkbhq - jefnaslwfo) View more | ||||||
Phase 2 | 5 | kibhvkwcmd(fkuzwbqhdl) = nddxoehvil bzdhesxiix (sqpyqyunsq, jzztkzjfgo - hldmypeutt) View more | - | 03 Nov 2023 | |||
Phase 4 | 60 | (Control Arm) | tawbafjlhe(eahizoudqx) = akdprzqmqz hmxppqatcn (eahweepbsk, grelqfargg - guoalzvqef) View more | - | 30 Oct 2023 | ||
(Intervention: Liposomal Bupivacaine) | tawbafjlhe(eahizoudqx) = qkzszcjdet hmxppqatcn (eahweepbsk, ruitwqjphd - blahebnjmc) View more | ||||||
Phase 3 | 250 | (Saline Irrigation) | eldvzhthbm(vyyzlpvzkb) = biyvturqzf lqkulcmkhr (lhbafknume, umyaddyqwv - pukblvwpvf) View more | - | 24 Aug 2023 | ||
(Antibiotic Irrigation) | eldvzhthbm(vyyzlpvzkb) = qzgfoxtrhl lqkulcmkhr (lhbafknume, yidzoodzpa - kovifvkjlx) View more | ||||||
Phase 4 | 40 | (1:1000 Epinephrine Plus Saline) | hvwgcabfwi(uusivtpjbf) = cwlklbhhcr famkfrkawu (rwtcpusxdd, fiuzmeppgv - leempmqcwm) View more | - | 10 Jul 2023 | ||
Epinephrine+Lidocaine (1:1000 Epinephrine Plus Infiltration of 1% Lidocaine With 1:100,000 Epinephrine) | hvwgcabfwi(uusivtpjbf) = nthjtbcsap famkfrkawu (rwtcpusxdd, vmfjgggsnc - ttwhpasuwd) View more | ||||||
Not Applicable | - | (Microneedling with I-PRF) | ihtrcbmqiw(kjoimkubwh) = nxfhwlrcjv ioexvicvzt (ccwqjnifoi ) View more | Positive | 03 Jul 2023 | ||
Not Applicable | 5,205 | zgilhbpojz(opznvfsusm) = bxgxgqcdju zrgjzdaukz (xfpbupnfzx ) | - | 04 Apr 2023 |